Vir Biotechnology (VIR) EBT (2018 - 2026)
Vir Biotechnology recorded quarterly EBT of -$125.5 million in Q1 2026, down 191.51% quarter-over-quarter from -$43.1 million in Q4 2025, and down 3.78% year-over-year from -$130.5 million in Q1 2025.
Vir Biotechnology's EBT history runs 9 years deep, the most recent figure standing at -$125.5 million for Q1 2026.
- In Q1 2026, EBT fell 3.78% year-over-year to -$125.5 million; the TTM figure through Mar 2026 stood at -$442.3 million (up 23.61% YoY), while the FY2025 annual figure was -$437.8 million, up 16.31% from the prior year.
- EBT came in at -$125.5 million for Q1 2026 at Vir Biotechnology, down from -$43.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of $921.9 million in Q1 2022 to a low of -$233.7 million in Q2 2022.
- A 5-year average of -$56.5 million and a median of -$125.5 million in 2026 frame the typical range for EBT.
- On a YoY basis, EBT climbed as much as 646.43% in 2022 and fell as far as 477.79% in 2022.
- Vir Biotechnology's EBT stood at -$151.6 million in 2022, then climbed by 20.36% to -$120.8 million in 2023, then grew by 13.32% to -$104.7 million in 2024, then jumped by 58.86% to -$43.1 million in 2025, then plunged by 191.51% to -$125.5 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$125.5 million, -$43.1 million, and -$163.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.31 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.18 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 831.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 221.65 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | -125.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -125.53 Mn |
| Dec 31, 2025 | -43.06 Mn |
| Sep 30, 2025 | -162.97 Mn |
| Jun 30, 2025 | -110.79 Mn |
| Mar 31, 2025 | -120.95 Mn |
| Dec 31, 2024 | -104.68 Mn |
| Sep 30, 2024 | -213.54 Mn |
| Jun 30, 2024 | -139.89 Mn |
| Mar 31, 2024 | -65.00 Mn |
| Dec 31, 2023 | -120.76 Mn |
| Sep 30, 2023 | -166.63 Mn |
| Jun 30, 2023 | -197.62 Mn |
| Mar 31, 2023 | -143.19 Mn |
| Dec 31, 2022 | -151.64 Mn |
| Sep 30, 2022 | 217.73 Mn |
| Jun 30, 2022 | -233.72 Mn |
| Mar 31, 2022 | 921.91 Mn |
| Dec 31, 2021 | 545.89 Mn |
| Sep 30, 2021 | 110.76 Mn |
| Jun 30, 2021 | 61.87 Mn |
| Mar 31, 2021 | -168.72 Mn |
| Dec 31, 2020 | -116.77 Mn |
| Sep 30, 2020 | -84.59 Mn |
| Jun 30, 2020 | -31.12 Mn |
| Mar 31, 2020 | -77.22 Mn |
| Dec 31, 2019 | -63.62 Mn |
| Sep 30, 2019 | -48.33 Mn |
| Jun 30, 2019 | -33.91 Mn |
| Mar 31, 2019 | -28.67 Mn |
| Dec 31, 2018 | -26.37 Mn |
| Sep 30, 2018 | -33.46 Mn |